A new risk score can help predict which pancreatic cancer survivors are more likely to suffer a recurrence of their cancer, ...

A new risk score may identify patients with node-negative pancreatic neuroendocrine tumors who face a high risk for ...

An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Investigators compared patient-reported cancer-related cognitive impairment between pre- and postmenopausal women with breast cancer who received endocrine therapy with or without chemotherapy.

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...

"We have known that income level is associated with incidence of poor-prognosis triple-negative breast cancer, but our new study presents the first data to show that income level impacts survival even ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...